Symptoms from Diagnostic Imaging of Other Cancers can be Used for Early Detection of Pancreatic Cancers

Atanas Hilendarov*

Received : July 15, 2026 | Published : July 27, 2026

Citation: Hilendarov A. Symptoms from Diagnostic Imaging of Other Cancers can be Used for Early Detection of Pancreatic Cancers. J Case Rep Rev Med. 2026;2(3):1-5. DOI: 10.64978/jcrrm.2026.07270124

Abstract

The implementation of effective early detection programs has significantly improved treatment, prognosis, and life expectancy in breast prostate, and colorectal cancers. Early-detection methods need to be developed for pancreatic ductal adenocarcinoma (PDAC), where progress during the past decades has remained slow.

Aim: The aim is to find and implement effective programs for early detection and significant improvement of treatment, prognosis and life expectancy in pancreatic cancer.

Material and Methods: We trying to use the experience from breast cancer, prostate cancer, and colorectal cancer to develop methods for early detection of pancreatic ductal adenocarcinoma (PDAC). A major breakthrough in early detection of PDAC will occur only through an interdisciplinary collaborative eff ort involving a critical mass of committed academic research institutions.

Results and Discussions: Pancreatic ductal adenocarcinoma (PDAC) has a devastating prognosis. Individuals and families face a bleak future and struggle with the lack of understanding of the disease, its etiology, and the dearth of treatment options. The 5-year survival rate of PDAC is only 8%, making it one of the deadliest human cancers. Major breakthrough are urgently needed in early diagnosis, treat-men, and the eventual prevention of PDAC.

Conclusion: It is clear that in other cancers, the implementation of effective early detection programs has significantly improved treatment, prognosis, and life expectancy. It is imperative that effective early detection methods be developed for PDA.

Keywords: Pancreatic ductal adenocarcinoma (PDAC); Early cancer detection; Survival rate; Interdisciplinary collaboration; Comparative oncology; Cancer screening; Diagnostic imaging; Biomarkers.